SRR934947
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.505
- TGF_BETA_SIGNALING+0.477
- WNT_BETA_CATENIN_SIGNALING+0.432
- HEDGEHOG_SIGNALING+0.341
- MYC_TARGETS_V2+0.328
- UV_RESPONSE_DN+0.305
- MITOTIC_SPINDLE+0.304
- APICAL_SURFACE+0.208
- PANCREAS_BETA_CELLS+0.169
- GLYCOLYSIS+0.147
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.302
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.283
- ANGIOGENESIS-0.242
- MYOGENESIS-0.219
- ALLOGRAFT_REJECTION-0.208
- CHOLESTEROL_HOMEOSTASIS-0.207
- INTERFERON_GAMMA_RESPONSE-0.206
- TNFA_SIGNALING_VIA_NFKB-0.201
- KRAS_SIGNALING_DN-0.180
- COAGULATION-0.169
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | DD58135A-FE4D-4B43-BEED-485D7A48C9F3 | — | — | 0.772 |
| 2 | SRR934858 | — | — | 0.741 |
| 3 | E6090BC6-D29D-4401-990A-251930CC6853 | — | — | 0.729 |
| 4 | 221384A6-059C-4731-9BD0-68EC9CA5651D | — | — | 0.724 |
| 5 | A548DB97-6D28-4DEA-8334-201093A67B1E | — | — | 0.723 |
| 6 | ED6F62A6-64A8-4919-B32C-8D3D86A0F9FF | — | — | 0.722 |
| 7 | 4549956C-8D25-4B37-894C-E82D5C7684F0 | — | — | 0.715 |
| 8 | 9CC5EB30-A8C2-4FDF-8074-467AA98ED1CA | — | — | 0.695 |
| 9 | SRR934728 | — | — | 0.685 |
| 10 | D2CDDB70-B27F-4D0A-A089-D92EEF1B75F8 | — | — | 0.685 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.505 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.477 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.432 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.341 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.328 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.305 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.304 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.208 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.169 | Cobimetinib | — uncovered |
| GLYCOLYSIS | 0.147 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.144 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.117 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.098 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.042 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.016 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.016 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.009 | Remibrutinib | — uncovered |